Literature DB >> 14580889

Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol.

Jenny Rönnmark1, Caroline Kampf, Anna Asplund, Ingmarie Höidén-Guthenberg, Kenneth Wester, Fredrik Pontén, Mathias Uhlén, Per-Ake Nygren.   

Abstract

Recombinant immunoconjugates constitute a novel class of immunoassay reagents produced by genetic fusion between an antigen recognizing moiety and a reporter enzyme or fluorescent protein, obviating the need for chemical coupling. In this work, we describe the construction, Escherichia coli production and characterization of recombinant beta-galactosidase (beta-gal)-based immunoconjugates directed to human immunoglobulin A (IgA). As the antigen recognizing moieties, either monovalent or dimeric (head-to-tail) versions of an IgA-specific affibody (Z(IgA1)) were used, previously selected in vitro from a protein library based on combinatorial engineering of a single staphylococcal protein A domain. To increase the likelihood of proper presentation on the assembled homotetrameric enzyme surface, the affibody moieties were linked to the N-terminus of the enzyme subunits via a heptapeptide linker sequence. The two resulting immunoconjugates Z(IgA1)-beta-gal and (Z(IgA1))(2)-beta-gal, containing four and eight affibody moieties per enzyme, respectively, could be expressed as soluble and proteolytically stable proteins intracellularly in E. coli from where they were purified to high purity by a single anion exchange chromatography step. The yields of immunoconjugates were in the range 200-400 mg/l culture. Biosensor-binding studies showed that both the Z(IgA1)-beta-gal and (Z(IgA1))(2)-beta-gal immunoconjugates were capable of selective IgA-recognition, but with an apparent higher binding affinity for the variant containing divalent affibody moieties, presumably due to avidity effects. The applicability of this class of recombinant immunoconjugates was demonstrated by IgA detection in enzyme-linked immunosorbent assay (ELISA) and dot-blot analyses. In addition, using human kidney biopsy samples from a nephropathy patient, IgA depositions in glomeruli could be detected by immunohistochemistry with low background staining of tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580889     DOI: 10.1016/j.jim.2003.06.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

Authors:  Torun Engfeldt; Anna Orlova; Thuy Tran; Alexander Bruskin; Charles Widström; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

2.  Beyond Antibodies: Development of a Novel Protein Scaffold Based on Human Chaperonin 10.

Authors:  Abdulkarim M Alsultan; David Y Chin; Christopher B Howard; Christopher J de Bakker; Martina L Jones; Stephen M Mahler
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

3.  Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by ZHER2-Idarubicin Conjugate: An in vitro Study.

Authors:  Leila Siavoshinia; Mostafa Jamalan; Majid Zeinali; Aminollah Pourshohod; Mahdie Koushki; Bahman Moradipoodeh; Ghorban Mohammadzadeh
Journal:  Iran J Pathol       Date:  2020-12-20

Review 4.  Prokaryotic expression of antibodies and affibodies.

Authors:  Luis Angel Fernández
Journal:  Curr Opin Biotechnol       Date:  2004-08       Impact factor: 9.740

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.